Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 42 clinical trials
Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease (VEDO-PREDIRESP)

Vedolizumab (VDZ) is a monoclonal antibody which has shown its efficacy in Crohn's disease by inducing and maintaining clinical response/remission. The French marketing authorization was

antibiotic therapy
tumour necrosis
vedolizumab
crohn's disease
antibiotics
  • 0 views
  • 26 Jan, 2022
  • 4 locations
Curcumin Supplementation as an Add on Treatment for Patients With Inflammatory Bowel Diseases Treated With Vedolizumab

increased cytokine secretion including TNF-. A main effective therapeutic interventions is blocking TNF. Vedolizumab, an anti integrin, is a new class of treatment designed to block trafficking of

enteropathy
ulcerative colitis
endoscopy
tumor necrosis factor
ulceration
  • 0 views
  • 26 Jan, 2021
  • 1 location
Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy (CYTOVEDO)

-integrin therapy, vedolizumab, can be proposed. The efficacy of vedolizumab has been assessed in a phase 3 study (GEMINI I), with response rates of 41.1% with vedolizumab vs 25.5% with placebo.

  • 0 views
  • 22 Apr, 2022
  • 5 locations
A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, people with ulcerative colitis or Crohn's disease will be treated with vedolizumab

conventional treatment
ulcerative colitis
vedolizumab
crohn's disease
ulceration
  • 0 views
  • 22 Mar, 2022
  • 1 location
Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab

Inflammatory bowel disease (IBD) is a chronic inflammatory state of the gastrointestinal tract(1) affecting 1.6-3.1 million people in the United States. Patients with IBD are treated with immunosuppressants that increase their risk of herpes zoster (HZ), also known as shingles. Those with IBD have a two-fold increased risk for HZ …

ulceration
shingrix
vedolizumab
golimumab
subunit vaccine
  • 36 views
  • 29 May, 2022
  • 1 location
A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

The main aim of the study is to learn if 4-weekly vedolizumab improves symptoms of Japanese participants with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD). Vedolizumab is

hematochezia
ulcerative colitis
endoscopy
ulceration
ulcerative colitis or crohn's
  • 0 views
  • 29 Jun, 2022
  • 16 locations
EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis (EFFICACI)

. Recently, a new biologic therapy blocking another target has been approved and is now reimbursed during ulcerative colitis, namely vedolizumab. Vedolizumab is an anti-integrin agent avoiding the

tumour necrosis
pancolitis
proctitis
vedolizumab
golimumab
  • 22 views
  • 16 Feb, 2022
  • 15 locations
A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study (LOVE-CD)

allowed in the latter group. Participants will be treated with 12 months of open label vedolizumab (study medication followed by commercial medication once reimbursement is available) and undergo

endoscopy
tumor necrosis factor
ulceration
immunosuppressive agents
corticosteroids
  • 2 views
  • 26 Jan, 2022
  • 17 locations
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

This phase I/II trial studies the side effects of infliximab and vedolizumab and to see how well they work in treating inflammation of the colon (colitis) caused by immune checkpoint inhibitor

monoclonal antibodies
genitourinary cancer
immune checkpoint inhibitor therapy
monoclonal protein
immune checkpoint inhibitor
  • 0 views
  • 30 Jun, 2022
  • 1 location
Impact of Anti-TNF Vedolizumab and Tofacitinib on Aortic Stiffness Carotid Intima-media Thickness and Cardiovascular Risk of Patients With Ulcerative Colitis

12 months of anti-TNF, vedolizumab and tofacitinib.

vedolizumab
golimumab
tumor necrosis factor
infliximab
adalimumab
  • 0 views
  • 18 Jul, 2021
  • 1 location